Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions (Q28200895)

Journal of Cardiovascular Pharmacology and Therapeutics

Europe PubMed Central

title

Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions (English)

0 references

1 reference

cardiovascular disease

1 reference

1

Charles H Hennekens

0 references

author name string

Oksana Sechenova

series ordinal

2

0 references

Danielle Hollar

series ordinal

3

0 references

Victor L Serebruany

series ordinal

4

0 references

language of work or name

English

0 references

publication date

September 2006

0 references

published in

0 references

volume

11

0 references

issue

3

0 references

page(s)

170-6

0 references

cites work

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1177/1074248406292263

Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials

21 April 2017

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Terms and conditions: semantic complexity and aspirin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406292263